Treatment of Acute Tubular Necrosis (ATN)
Diagnosis and Etiology
- ATN is the most common cause of intrinsic acute kidney injury (AKI) in hospitalized patients, accounting for approximately 68% of AKI cases in patients with decompensated cirrhosis 1
Immediate Management
- Discontinue all nephrotoxic medications (e.g., NSAIDs, aminoglycosides, contrast agents) to prevent further kidney damage in patients with ATN 1
- Aggressive fluid resuscitation with crystalloids is indicated in cases of hypovolemia or decreased effective arterial blood volume in patients with ATN 1, 2
- In patients with tense ascites, therapeutic paracentesis with albumin infusion may improve renal function in patients with ATN 1
- For patients with volume depletion and no response to initial fluid resuscitation, 20% albumin solution at 1 g/kg (maximum 100 g) for two consecutive days should be considered in patients with ATN 1
Renal Replacement Therapy
- Indications for dialysis include severe or refractory hyperkalemia, metabolic acidosis, volume overload unresponsive to diuretics, and uremic symptoms (encephalopathy, pericarditis) in patients with ATN 2
- Continuous veno-venous hemofiltration (CVVH) may be beneficial in patients with severe renal dysfunction and refractory fluid retention in patients with ATN 2
- When combined with positive inotropic agents, CVVH may increase renal blood flow, improve renal function, and restore diuretic efficacy in patients with ATN 2
Prognosis
- Approximately 37.1% of hospitalized patients with ATN die, according to the European Heart Association 2
Management of Acute Tubular Necrosis (ATN)
Diagnosis and Etiology
- The American Association for the Study of Liver Diseases recommends therapeutic paracentesis with albumin infusion to improve renal function in patients with cirrhosis and tense ascites 3
Monitoring and Follow-up
- The National Kidney Foundation recommends that patients who recover from ATN should be evaluated for new onset or worsening of pre-existing chronic kidney disease at 3 months, with long-term follow-up important as CKD following AKI is typically a late event, with studies showing follow-up ranges of 12-74 months 4
Management of Acute Tubular Necrosis (ATN)
Immediate Interventions
- The American Gastroenterological Association recommends stopping all nephrotoxic medications immediately, including NSAIDs, aminoglycosides, ACE inhibitors, ARBs, and contrast agents, in patients with ATN 5
- The American Association for the Study of Liver Diseases suggests withdrawing diuretics after ATN diagnosis is confirmed, as part of the management strategy for patients with ATN 6
- The American Gastroenterological Association recommends albumin as superior to crystalloids in patients with cirrhosis and ATN, for improving renal function 7, 8
Supportive Care Measures
- The American Association for the Study of Liver Diseases recommends avoiding prophylactic bladder catheterization, as part of the infection prevention strategy for patients with ATN 6
- The American Association for the Study of Liver Diseases suggests considering withholding non-selective beta-blockers, particularly in hypotensive patients with ATN 6
- The American Association for the Study of Liver Diseases recommends measuring urine output daily, as oliguria is associated with poor prognosis in patients with ATN 6
- The American Gastroenterological Association suggests monitoring serum creatinine daily to assess AKI stage in patients with ATN 5
Management of Acute Tubular Necrosis with Anuria
Renal Replacement Therapy Indications
- The American Association for the Study of Liver Diseases recommends initiating RRT based on clinical grounds when severe or refractory hyperkalemia is present, as indicated by the Hepatology society 9
- Continuous RRT (CVVH) is preferred over intermittent hemodialysis in hemodynamically unstable patients, according to the Hepatology society 9
Infection Prevention
- The Journal of Hepatology society recommends screening and treating infections aggressively in patients with ATN 10
Acute Tubular Necrosis Management
Supportive Care Measures
- The American Journal of Kidney Diseases recommends providing enteral nutrition preferentially over parenteral in severely malnourished patients, which may improve survival, with a target total energy intake of 20-30 kcal/kg/day and protein intake of 0.8-1.0 g/kg/day in non-catabolic patients without dialysis, and 1.0-1.5 g/kg/day if on renal replacement therapy 11
- The Hepatology society suggests avoiding prophylactic antibiotics in ATN patients, as their efficacy is unproven 12
Renal Replacement Therapy Indications
- The European Heart Journal recommends using continuous veno-venous hemofiltration (CVVH) in hemodynamically unstable patients, as it may increase renal blood flow and restore renal function when combined with positive inotropic agents 13
Special Populations
- The Hepatology and Journal of Hepatology societies note that differentiating ATN from hepatorenal syndrome is challenging, and both may require similar supportive care initially, with a consideration for withholding non-selective beta-blockers in cirrhotic patients with ATN 12, 14
Key Diagnostic Considerations
- The European Heart Journal suggests that a fractional excretion of sodium (FENa) >1% indicates ATN, while <1% suggests prerenal azotemia 13
- The Hepatology society recommends using urinary biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) to help differentiate ATN from other AKI causes 12